Table 6.
Percentage of US Adults, Overall and in Selected Subgroups, Taking Antihypertensive Medication Who Meet BP Treatment Goal per ACC/AHA Guideline, 2014 Expert Panel Report, and JNC7 Based on the 2013 to 2016 PINNACLE Registry Data
| Subgroups | ACC/AHA guideline | 2014 Report | Difference between ACC/AHA guideline and 2014 report | JNC7 | Difference between ACC/AHA guideline and JNC7 |
|---|---|---|---|---|---|
| Overall (N=3 405 189) | 41.24 (41.19–41.30) | 79.41 (79.36–79.45) | 38.16 (38.11–38.21) | 64.30 (64.25–64.35) | 23.06 (23.01–23.10) |
| Age group, y | |||||
| 18–44 (N=205 638) | 39.64 (39.43–39.86) | 73.46 (73.27–73.65) | 33.81 (33.61–34.02) | 67.96 (67.76–68.16) | 28.32 (28.12–28.51) |
| 45–54 (N=376 824) | 37.03 (36.88–37.19) | 72.52 (72.38–72.66) | 35.49 (35.34–35.64) | 64.56 (64.41–64.72) | 27.53 (27.39–27.67) |
| 55–64 (N=742 428) | 39.34 (39.23–39.45) | 77.31 (77.21–77.40) | 37.97 (37.86–38.08) | 63.97 (63.86–64.08) | 24.63 (24.53–24.73) |
| 65–74 (N=1 027 950) | 41.38 (41.29–41.48) | 81.68 (81.60–81.75) | 40.29 (40.20–40.39) | 63.40 (63.30–63.49) | 22.01 (21.93–22.09) |
| ≥75 (N=1 052 349) | 44.27 (44.18–44.37) | 82.30 (82.22–82.37) | 38.03 (37.93–38.12) | 64.61 (64.52–64.70) | 20.34 (20.26–20.42) |
| Men (N=1 747 780) | 42.15 (42.07–42.22%) | 79.88 (79.82–79.94) | 37.73 (37.66–37.81) | 65.10 (65.03–65.17) | 22.96 (22.89–23.02) |
| Women (N=1 654 071) | 40.29 (40.21–40.36) | 78.90 (78.84–78.96) | 38.61 (38.54–38.69) | 63.46 (63.38–63.53) | 23.17 (23.10–23.23) |
| Race and ethnicity | |||||
| White (N=2 150 367) | 42.35 (42.28–42.41) | 80.86 (80.81–80.91) | 38.51 (38.45–38.58) | 65.74 (65.67–65.80) | 23.39 (23.33–23.44) |
| Black (N=250 690) | 30.38 (30.20–30.56) | 67.57 (67.39–67.75) | 37.19 (37.00–37.38) | 51.31 (51.12–51.51) | 20.93 (20.77–21.09) |
| Other * (N=16 685) | 41.14 (40.40–41.90) | 76.82 (76.17–77.46) | 35.67 (34.95–36.41) | 61.07 (60.33–61.81) | 19.93 (19.32–20.54) |
| Hispanic (N=145 086) | 39.08 (38.83–39.33) | 76.43 (76.21–76.64) | 37.34 (37.10–37.59) | 59.67 (59.42–59.92) | 20.59 (20.38–20.80) |
| Non‐Hispanic (N=3 260 103) | 41.34 (41.29–41.39) | 79.54 (79.50–79.58) | 38.20 (38.15–38.25) | 64.51 (64.46–64.56) | 23.17 (23.12–23.21) |
| 10‐y ASCVD risk categories, % | |||||
| <5 (N=11 128) | 42.57 (41.65–43.49) | 79.46 (78.69–80.20) | 36.89 (35.99–37.79) | 75.66 (74.85–76.45) | 33.09 (32.21–33.97) |
| 5–<10 (N=11 207) | 37.06 (36.16–37.96) | 77.43 (76.65–78.20) | 40.38 (39.47–41.29) | 67.90 (67.02–68.76) | 30.84 (29.98–31.70) |
| 10–<20 (N=15 449) | 34.91 (34.16–35.67) | 76.20 (75.52–76.87) | 41.28 (40.51–42.07) | 60.11 (59.33–60.88) | 25.19 (24.51–25.88) |
| ≥20 (N=16 053) | 26.82 (26.14–27.52) | 67.28 (66.55–68.00) | 40.45 (39.69–41.22) | 42.85 (42.08–43.62) | 16.02 (15.46–16.60) |
| History of CVD (N=1 896 465) | 44.47 (44.40–44.54) | 81.26 (81.21–81.32) | 36.79 (36.72–36.86) | 65.57 (65.51–65.64) | 21.10 (21.05–21.16) |
Proportions and 95% Clopper‐Pearson (exact) CIs were reported. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic CVD; BP, blood pressure; CVD, cardiovascular disease; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; and PINNACLE, Practice Innovation and Clinical Excellence.
*Defined as combination of any race other than White or Black, including Asian, American Indian/Alaskan Native, Native Hawaiin/ Pacific Islander.